Lin BioScience, Inc. (TPEX: 6696)
Taiwan
· Delayed Price · Currency is TWD 157.00
+2.50 (1.62%)
Nov 19, 2024, 2:59 PM CST
Lin BioScience Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Net Income | -731.66 | -687.19 | -313.52 | -434.7 | -151.84 | -235.26 | Upgrade
|
| Depreciation & Amortization | 19 | 17.93 | 11.16 | 4.39 | 4.08 | 4 | Upgrade
|
| Other Amortization | - | - | - | - | - | 0.32 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | -0.22 | - | 0.48 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | - | - | -0.46 | Upgrade
|
| Stock-Based Compensation | 158.25 | 115.15 | 44.39 | 8.91 | 0.93 | 1.13 | Upgrade
|
| Other Operating Activities | -512.32 | -378.32 | -105.16 | 105.77 | -22.4 | 0 | Upgrade
|
| Change in Accounts Receivable | 0.03 | -25.02 | 1.46 | -1.48 | - | 7.99 | Upgrade
|
| Change in Accounts Payable | -18.24 | 60.64 | 13.32 | 19.46 | -7.23 | 19.02 | Upgrade
|
| Change in Other Net Operating Assets | -98.54 | -116.02 | -12.66 | 8.02 | -4.14 | -7.22 | Upgrade
|
| Operating Cash Flow | -1,183 | -1,013 | -361.01 | -289.84 | -180.61 | -210.02 | Upgrade
|
| Capital Expenditures | -5.49 | -1.97 | -22.38 | -2.12 | -0.57 | -2.34 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.51 | - | - | Upgrade
|
| Investment in Securities | -2,919 | - | - | - | - | 101.21 | Upgrade
|
| Other Investing Activities | 5.16 | 3.83 | -1.67 | 0.13 | 0.78 | 0.44 | Upgrade
|
| Investing Cash Flow | -2,920 | 1.87 | -24.06 | -1.48 | 0.2 | 99.31 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | - | 59.96 | Upgrade
|
| Long-Term Debt Repaid | - | -11.86 | -5.53 | -2.91 | -2.83 | -2.4 | Upgrade
|
| Net Debt Issued (Repaid) | -13.58 | -11.86 | -5.53 | -2.91 | -2.83 | 57.56 | Upgrade
|
| Issuance of Common Stock | 655.07 | 622.41 | 511 | 31.23 | 915.26 | - | Upgrade
|
| Other Financing Activities | 2,590 | 2,026 | 624.32 | - | 247.93 | - | Upgrade
|
| Financing Cash Flow | 3,232 | 2,637 | 1,130 | 28.32 | 1,160 | 57.56 | Upgrade
|
| Foreign Exchange Rate Adjustments | 119.52 | -10.14 | 93.66 | -22.41 | -4.85 | 2.31 | Upgrade
|
| Net Cash Flow | -751.8 | 1,616 | 838.39 | -285.4 | 975.11 | -50.85 | Upgrade
|
| Free Cash Flow | -1,189 | -1,015 | -383.4 | -291.96 | -181.18 | -212.36 | Upgrade
|
| Free Cash Flow Per Share | -15.42 | -13.72 | -5.34 | -4.24 | -2.92 | -3.57 | Upgrade
|
| Cash Interest Paid | 1.18 | 1.21 | 0.88 | 0.07 | 0.13 | 0.05 | Upgrade
|
| Cash Income Tax Paid | - | -29.53 | -18.4 | -9.53 | -23.02 | -4.81 | Upgrade
|
| Levered Free Cash Flow | -743.86 | -635.88 | -658.48 | -31.55 | 142.18 | -125.71 | Upgrade
|
| Unlevered Free Cash Flow | -743.17 | -635.13 | -657.93 | -31.5 | 142.33 | -125.5 | Upgrade
|
| Change in Net Working Capital | 116.99 | 80.73 | 412.89 | -168.74 | -261.03 | -20.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.